 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
SPIRIT 2 is a randomized phase 3 clinical in patients with chronic myeloid leukaemia being conducted in the United Kingdom. The study compares the use of imatinib (the standard of care for CML Patients in the UK since 2003) with dasatinib, a second generation tyrosine kinase inhibitor, in patientd newly diagnosed with CML. It is the only first-line study to have long term (in this case 5 year) survival as the primary endpoint.
References
editExternal links
edit